SANGAMO THERAPEUTICS INC (SGMO)

US8006771062 - Common Stock

0.6247  +0.02 (+3.53%)

After market: 0.635 +0.01 (+1.65%)

Fundamental Rating

3

Overall SGMO gets a fundamental rating of 3 out of 10. We evaluated SGMO against 592 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. SGMO is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

SGMO had negative earnings in the past year.
In the past year SGMO has reported a negative cash flow from operations.
SGMO had negative earnings in each of the past 5 years.
In the past 5 years SGMO reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of SGMO (-156.00%) is worse than 87.59% of its industry peers.
Looking at the Return On Equity, with a value of -311.14%, SGMO is doing worse than 76.53% of the companies in the same industry.
Industry RankSector Rank
ROA -156%
ROE -311.14%
ROIC N/A
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.74, we must say that SGMO is in the distress zone and has some risk of bankruptcy.
SGMO's Altman-Z score of -11.74 is on the low side compared to the rest of the industry. SGMO is outperformed by 81.97% of its industry peers.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.74
ROIC/WACCN/A
WACC9.02%

2.3 Liquidity

SGMO has a Current Ratio of 1.98. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.98, SGMO is not doing good in the industry: 79.42% of the companies in the same industry are doing better.
A Quick Ratio of 1.98 indicates that SGMO should not have too much problems paying its short term obligations.
SGMO has a Quick ratio of 1.98. This is in the lower half of the industry: SGMO underperforms 77.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.98

5

3. Growth

3.1 Past

SGMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.60%.
Looking at the last year, SGMO shows a very strong growth in Revenue. The Revenue has grown by 58.35%.
Measured over the past years, SGMO shows a quite strong growth in Revenue. The Revenue has been growing by 15.84% on average per year.
EPS 1Y (TTM)-17.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-6.25%
Revenue 1Y (TTM)58.35%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Revenue growth Q2Q-92.49%

3.2 Future

Based on estimates for the next years, SGMO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.37% on average per year.
Based on estimates for the next years, SGMO will show a quite strong growth in Revenue. The Revenue will grow by 11.08% on average per year.
EPS Next Y66.63%
EPS Next 2Y28.97%
EPS Next 3Y17.24%
EPS Next 5Y19.37%
Revenue Next Year-70.97%
Revenue Next 2Y-39.07%
Revenue Next 3Y-27.35%
Revenue Next 5Y11.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SGMO's earnings are expected to grow with 17.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.97%
EPS Next 3Y17.24%

0

5. Dividend

5.1 Amount

SGMO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (3/27/2024, 8:00:03 PM)

After market: 0.635 +0.01 (+1.65%)

0.6247

+0.02 (+3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap111.77M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -156%
ROE -311.14%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.98
Quick Ratio 1.98
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y66.63%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)58.35%
Revenue growth 3Y14.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y